ZyVersa Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2021 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
ZyVersa Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2021 to Q1 2024.
  • ZyVersa Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $2.67M.
  • ZyVersa Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $5.96M, a 219% increase from 2022.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 $2.67M +$2.71M Mar 31, 2024 10-Q 2024-05-15
Q1 2023 -$34.7K -$2.73M -101% Mar 31, 2023 10-Q 2024-05-15
Q1 2022 $2.7M +$2.7M Mar 31, 2022 10-Q 2022-05-13
Q2 2021 $751K Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $667* Mar 31, 2021 10-Q 2022-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.